GlassScriptPhysician profile
David Shamblaw
NPI 1700843778
$545.92
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $23.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $136.96 | 2019 | |
| Viiv Healthcare Company | $117.88 | 2019-2020 | |
| Emd Serono, INC. | $94.94 | 2019 | |
| Janssen Biotech, INC. | $76.39 | 2019 | |
| Merck Sharp & Dohme LLC | $54.86 | 2019 | |
| Aytu Biopharma, INC. | $24.58 | 2019 | |
| Mylan Institutional INC. | $22.52 | 2019 | |
| Theratechnologies INC. | $17.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shamblaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.